• Our research theme is: Functional and therapeutic approaches of Proteinopathies and Intellectual Deficiency.
  • Our research projects focus on two main topics:
    •     Decipher molecular and pathophysiological mechanisms of these diseases.
    •     Identify new therapeutic avenues.
Publications related to Protein Misfolding Diseases
  • A. Bamia, M. Sinane, R. Naït-Saïdi, J. Dhiab, M. Keruzoré, PH. Nguyen, A. Bertho, F. Soubigou, S. Halliez, M. Blondel, C. Trollet, M. Simonelig, G. Friocourt, V. Béringue, F. Bihel, C. Voisset. Anti-prion drugs targeting the protein folding activity of the ribosome reduce PABPN1 aggregation. Neurotherapeutics 2021, 18(2):1137-1150.

  • O. Billant, G. Friocourt, P. Roux, C. Voisset. p53, A Victim of the Prion Fashion. Cancers (Basel). 2021;13(2):E269.

  • A. Malerba, F. Roth, P. Harish, J. Dhiab, N. Lu-Nguyen, O. Cappellari, S. Jarmin, A. Mahoudeau, V. Ythier, J. Lainé, E. Negroni, E. Abgueguen, M. Simonelig, P. Guedat, V. Mouly, G. Butler-Browne, C. Voisset, G. Dickson, C. Trollet. Guanabenz treatment improves Oculopharyngeal muscular dystrophy phenotype. Human Molecular Genetics 2019, 15;28(10):1694-1708.

  • C. Voisset, M. Blondel, GW. Jones, G. Friocourt, G. Stahl, S. Chédin, V. Béringue, Reynald Gillet. The double life of the ribosome: when its protein folding activity supports prion propagation. Prion 2017, 11(2):89-97. Invited review by the journal Prion following our publication in Scientific Reports.

  • Billant O, M. Blondel, C. Voisset. p53, p63 and p73 in the wonderland of S. cerevisiae. Oncotarget, 2017, 8(34):57855-57869.

  • Billant O, Léon A, Le Guellec S, Friocourt G, Blondel M, Voisset C. The dominant-negative interplay between p53, p63 and p73: A family affair. Oncotarget, 2016, doi: 10.18632/oncotarget.11774.

  • Blondel M, Soubigou F, Evrard J, Nguyen PH, Hasin N, Chédin S, Gillet R, Contesse MA, Friocourt G, Stahl G, Jones GW, Voisset C. Protein Folding Activity of the Ribosome is involved in Yeast Prion Propagation. Scientific Reports, 2016, 6, 32117.

  • Voisset C, Blondel M. Chemobiology at happy hour: yeast as a model for pharmacological screening. Med Sci (Paris). 2014, 30(12):1161-8.

  • Nguyen PH, Hammoud H, Halliez S, Pang Y, Evrard J, Schmitt M, Oumata N, Bourguignon JJ, Sanyal S, Béringue V, Blondel M, Bihel F, Voisset C. (2014). SAR Study around Guanabenz Identifies Two Derivatives Retaining Antiprion Activity but Having Lost α2-Adrenergic Receptor Agonistic Activity. ACS Chem Neurosci. 5(10):1075-82.

  • Nguyen PH, Oumata N, Soubigou F, Evrard J, Desban N, Lemoine P, Bouaziz S, Galons H, Blondel M and Voisset C. Evaluation of the antiprion activity of 6-aminophenanthridines and related heterocycles. European Journal of Medicinal Chemistry, 2014, 82:363-371.

  • Oumata N, Nguyen PH, Béringue V, Soubigou F, Pang Y, Desban N, Massacrier C, Morel Y, Paturel C, Contesse MA, Bouaziz S, Sanyal S, Galons H, Blondel M, Voisset C. The toll-like receptor agonist imiquimod is active against prions. PLoS ONE, 2013, 8(8):e72112.

  • Pang Y, Kurella S, Voisset C, Samanta D, Banerjee D, Schabe A, Das Gupta C, Galons H, Blondel M, Sanyal S. The antiprion compound 6-aminophenanthridine inhibits the protein folding activity of the ribosome by direct competition. J Biol Chem, 2013, 288(26):19081-9.

  • Dos Reis S., Pang Y., Vishnu N., Voisset C., Galons H., Blondel M., Sanyal S.. Mode of action of the antiprion drugs 6AP and GA on ribosome assisted protein folding. Biochimie, 2011, 93(6):1047-54.

  • N. Barbezier, A. Chartier, Y. Bidet, C. Voisset, H. Galons, M. Blondel & M. Simonelig. The antiprion drug 6-aminophenanthridine decreases the toxicity of mutant PABPN1 in a Drosophila model of oculopharyngeal muscular dystrophy. EMBO Molecular Medicine, 2011, 3(1):37-49.

  • C Voisset, SJ. Saupe and M Blondel. The various facets of the protein folding activity of the ribosome. Biotechnology Journal, 2011, 6(6):668-73.

  • Gug F., Oumata N., Tribouillard-Tanvier D., Voisset C, Desban N. Bach S., Blondel M & Galons H. Synthesis of conjugates of 6-aminophenanthridine and Guanabenz, two structurally unrelated prion inhibitors for the determination of their cellular targets by affinity chromatography. Bioconjugate Chemistry, 2010, 21(2): 279-288.

  • Voisset C, Saupe SJ, Galons H. and Blondel M. Procedure for identification and characterization of drugs efficient against mammalian prion: from a yeast-based antiprion drug screening assay to in vivo mouse models. Infectious Diseases, Drug Targets, 2009, 9(1) :31-39.

  • Voisset C, Thuret JY, Tribouillard-Tanvier D, Saupe SJ, Blondel M. Tools for the study of Ribosome-borne Protein Folding Activity (RPFA). Biotechnol J., 2008, 3(8):1033-40.

  • Tribouillard-Tanvier D, V Béringue, N Desban, F Gug, S Bach, C Voisset, H Galons, H Laude, D Vilette, M Blondel. Antihypertensive drug Guanabenz is active in vivo against both yeast and mammalian prions. PLoS ONE, 2008, 3(4):e1981.

  • Tribouillard-Tanvier D, S Dos Reis, F Gug, C Voisset, V Béringue, R Sabat, E Kikovska, N Talarek, S Bach, C Huang, N Desban, SJ. Saupe, S Supattapone, JY Thuret, S Chédin, D Vilette, H Galons, S Sanyal, and M Blondel. Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs. PLoS ONE, 2008, 3(5):e2174

Publications related to other research themes
  • Reznichenko O, Quillévéré A, Martins RP, Loaëc N, Kang H, Lista MJ, Beauvineau C, González-García J, Guillot R, Voisset C, Daskalogianni C, Fåhraeus R, Teulade-Fichou MP, Blondel M, Granzhan A. Novel cationic bis(acylhydrazones) as modulators of Epstein-Barr virus immune evasion acting through disruption of interaction between nucleolin and G-quadruplexes of EBNA1 mRNA. Eur J Med Chem. 2019, 178:13-29.

  • MJ. Lista, R. Prado Martins, MA. Contesse, S. Findakly, P. Pochard, C Daskalogianni, C. Guetta, C. Jamin, MP. Teulade-Fichou, R. Fåhraeus, C. Voisset* and M. Blondel*. Nucleolin is required for the Epstein-Barr virus-encoded 1 EBNA1 immune evasion through binding to G-quadruplexes of EBNA1 mRNA. Nat Comm 2017, 8:16043. doi: 10.1038/ncomms16043. *contributed equally.

  • Lista MJ, Martins RP, Angrand G, Quillévéré A, Daskalogianni C, Voisset C, Teulade-Fichou MP, Fåhraeus R, Blondel M. A yeast model for the mechanism of the Epstein-Barr virus immune evasion identifies a new therapeutic target to interfere with the virus stealthiness. Microb Cell. 2017, 4(9):305-307. doi: 10.15698/mic2017.09.590.

  • Daskalogianni C, Pyndiah S, Apcher S, Mazars A, Manoury B, Ammari N, Nylander K, Voisset C, Blondel M, Fåhraeus R. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers. J Pathol. 2015, 235(2):334-41.

  • Lista MJ, Voisset C, Contesse MA, Friocourt G, Daskalogianni C, Bihel F, Fåhraeus R, Blondel M (2015). The long-lasting love affair between the budding yeast Saccharomyces cerevisiae and the Epstein-Barr virus. Biotechnol J, 10(11):1670-81.

  • Voisset C, Daskalogianni C, Contesse MA, Mazars A, Arbach H, Le Cann M, Soubigou F, Apcher S, Fåhraeus R and Blondel M. A yeast-based assay identifies drugs that interfere with Epstein-Barr virus immune evasion. Diseases Mechanismes and Models, 2014, 7(4):435-44.

  • Aiyar RS, Bohnert M, Duvezin-Caubet S, Voisset C, Gagneur J, Fritsch ES, Couplan E, von der Malsburg K, Funaya C, Soubigou F, Courtin F, Suresh S, Kucharczyk R, Evrard J, Antony C, St Onge RP, Blondel M, di Rago JP, van der Laan M, Steinmetz LM. (2014). Mitochondrial protein sorting as a therapeutic target for ATP synthase disorders. Nat Commun. 5:5585.

  • Voisset C, García-Rodríguez N, Birkmire A, Blondel M, Wellinger RE (2014). Using yeast to model calcium-related diseases: Example of the Hailey-Hailey disease. Biochim Biophys Acta, Molecular Cell Research 1843:2315–2321.

  • Griffiths D.J and C.Voisset. Human endogenous retroviruses: from ancestral pathogens to bona fide genes. Microbiology Today, 2008, 35: 30-33

  • Voisset C, R.A. Weiss, D.J. Griffiths. Human RNA « rumor » viruses : the search for novel human retroviruses in chronic disease. Microbiology and Molecular Biology Reviews, 2008, 72(1) : 157-196.

  • Voisset C, Lavie M, Helle F, Op De Beeck A, Bilheu, Bertrand-Michel J, Tercé F, Cocquerel L, Wychowski C, Vu-Dac N and Dubuisson J. Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry. Cellular Microbiology, 2008, 10 (3) : 606-617

  • Helle F, Goffard A, Morel V, Duverlie G, McKeating J, Keck Z-Y, Foung S, Penin F, Dubuisson J, Voisset C. The neutralizing activity of anti-HCV antibodies is modulated by specific glycans on the E2 envelope protein. Journal of Virology, 2007, 81 (15) : 8101-8111.

  • Johansson DX, Voisset C, Tarr AW, Aung M, Ball JK, Dubuisson J and Persson MAA. Broadly neutralizing human antibodies mapped to a CD81 binding region of the Hepatitis C virus glycoprotein E2. Proc Natl Acad Sci U S A., 2007, 104(41):16269-16274.

  • Lavie M, Voisset C, Wychowski C, Vu-Dac N, Duverlie G, Dubuisson J. SAA inhibits HCV entry. Hepatology, 2006, 44 (6):1626-34.

  • Voisset C, Op de Beeck AO, Horellou P, Dreux M, Gustot T, Duverlie G, Cosset FL, Vu-Dac N, Dubuisson J. High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. J Gen Virol, 2006; 87(Pt 9):2577-81.

  • Helle F, Wychowski C, Vu-Dac N, Gustafson KR, Dubuisson J, Voisset C. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J Biol Chem, 2006, 281(35):25177-83.

  • Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, Keck Z, Foung S, Vu-Dac N, Dubuisson J, Bartenschlager R, Lavillette D, Cosset FL. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem, 2006, 281(27):18285-95.

  • Cocquerel L*, Voisset C*, Dubuisson J. Hepatitis C virus entry: potential receptors and their biological functions. J Gen Virol, 2006, 87(Pt 5):1075-84. *contributed equally.

  • Rouillé Y, Helle F, Delgrange D, Roingeard P, Voisset C, Blanchard E, Belouzard S, McKeating J, Patel AH, Maertens G, Wakita T, Wychowski C, Dubuisson J.  Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol, 2006, 80(6):2832-41.

  • Voisset C, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, Vu-Dac N. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem, 2005, 280(9):7793-7799

  • Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, Bain C, Patel AH, Dubuisson J, Ball JK, Cosset FL. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology. 2005, 41(2):265-274.

  • Voisset C, Dubuisson J. Functional hepatitis C virus envelope glycoproteins. Biol Cell, 2004, 96(6):413-20.

  • Op De Beeck A.*, Voisset C.*, Bartosch B., Ciczora Y, Cocquerel L., Keck Z., Foung S., Cosset FL. and Dubuisson J. Characterization of Functional Hepatitis C Virus Envelope Glycoproteins J Virol., 2004, 78(6):2994-3002. * contributed equally.

  • Voisset C., R.E. Myers, A. Carne, P. Kellam and D.J. Griffiths. Rabbit endogenous retrovirus-H encodes a functional protease. J Gen Virol. 2003, 84(Pt1):215-225.

  • Griffiths D.J., Voisset C., Venables P.J.W. and Weiss R.A. A novel endogenous retrovirus in rabbits previously reported as human retrovirus 5. J Virol. 2002, 76(14):7094-7102.

  • Voisset C., Tönjes R.R., Breyton P., Mandrand B., Paranhos-Baccalà G. Specific detection of RT activity in culture supernatants of retrovirus-producing cells, using synthetic DNA as competitor in polymerase enhanced reverse transcriptase assay. J Virol Methods. 2001, 94(1-2):187-193.

  • Voisset C., Bouton O., Bedin F., Duret L., Mandrand B., Mallet F., Paranhos-Baccalà G. Chromosomal distribution and coding capacity of the human endogenous retrovirus HERV-W family. AIDS Res Hum Retroviruses. 2000, 16(8):731-740.

  • Voisset C., Mandrand B., Paranhos-Baccalà G. RNA amplification technique, NASBA, also amplifies homologous plasmid DNA in non-denaturing conditions. Biotechniques. 2000, 29(2):236-238.

  • Voisset C., Blancher A., Perron H., Mandrand B., Mallet F., Paranhos-Baccalà G. Phylogeny of a novel family of human endogenous retrovirus sequences, HERV-W, in humans and other primates. AIDS Res Hum Retroviruses. 1999, 15(17):1529-1533.

  • Elaissari A., Holt L., Meunier F., Voisset C., Pichot C., Mandrand B., Mabilat C. Hydrophilic and cationic latex particles for the specific extraction of nucleic acids. J Biomater Sci Polym Ed. 1999, 10(4):403-420.

  • Perron H., Garson J.A., Bedin F., Beseme F., Paranhos-Baccalà G., Komurian-Pradel F., Mallet F., Tuke P.W., Voisset C., Blond J.L., Lalande B., Seigneurin J.M., Mandrand B. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. Proc Natl Acad Sci U S A. 1997, 94(14):7583-7588.

Post-doc Fellows
Olivier Billant (ATER, 2016-2018)
Adeel Nasir (UBO, 2019-2021)

PhD Students
François Helle (Université de Lille, 2007)
Phu hai Nguyen (UBO, 2013)
Maria Jose Lista (UBO, 2016)
Olivier Billant (UBO, 2016)
Aline Bamia (UBO, 2019)
Maha Sinane (ongoing since 2019)
Lucile Gentile (ongoing since 2021)

Master 2 Students
Marie Le Cann (Inserm School, 2009)
Olivier Billant (UBO, 2012)
Maria José Lista (Uruguay University, 2012)
Maha Sinane (UBO, 2019)
Lucile Gentile (Perpignan University, 2021)

Master 1 Students
Eric Guévellou (UBO, 2009)
Olivier Billant (UBO, 2011)
A. Vercauteren Drubbel (Bruxelles University, 2012)
Danilo Segovia (Uruguay University, 2013)
Solenn Le Guellec (Inserm School, 2014)
Alice Léon (UBO, 2014)
Madeline Falatas (UBO, 2015)
Mégane Collobert (UBO, 2016)
Pierre Coutrot (UBO, 2019)
Johan Natter (Strasbourg University, 2020)
Chloé Page (UBO, 2021)
Solenn Buan (UBO, 2022)

Licence, IUT and BTS Students
Marion Jaboulet (Lyon University, 1998)
Perrine Breyton (Lyon University, 1999)
Post-graduate students (UCL, 2001)
Fanny Denis (Lille University, 2003-2004)
Pauline Horellou (Lille University, 2004-2005)
Angéline Bilheu (Lille University, 2005-2006)
Sabah El Barkani (Lille University, 2006-2007)
Flavie Soubigou (Lille University, 2008-2009)
Agathe Bertho (IUT Quimper, 2018)
Victorien Chaker (UBO, 2019)

Master 1 Médecine, UBO, Brest
-UE Microbiote et Biodiversité en santé humaine
-UE modèles animaux et mécanismes physiopathologiques

Master 1 Biologie-Santé, UBO, Brest
-UE Protéomique et génomique

Master 1 Microbiologie, UBO, Brest
-UE Gestion du risque Microbiologique

Master 2 de Neurosciences, Brest, Rennes, Nantes, Angers
-UE Recherche translationnelle

Current position:

  • Co-direction of the PRiME Group, BIGG Team, Inserm UMR 1078, School of medicine of Brest, France
    • Research theme: Molecular mechanisms and therapeutics of Protein Misfolding Diseases
      • Neurodegenerative diseases (Prion Diseases, Parkinson's disease, Alzheimer's disease)
      • Neurodevelopmental diseases (Partington syndrome)
      • Metabolic diseases (Type 2 diabetes)
      • Neuromuscular diseases (Oculopharyngeal muscular dystrophy OPMD in collaboration)
    • Lab director: Emmanuelle Génin


  • Graduate student in Ecole Normale Supérieure (ENS) & Claude Bernard University Lyon I, France
  • PhD Student, CNRS-bioMérieux UMR103 research unit, ENS, Lyon, France
    • Research theme: Human endogenous retroviruses and multiple sclerosis
    • PhD Director: Glaucià Paranhos-Baccalá
    • Lab director: Bernard Mandrand

Professional experiences:

  • Post-doctoral fellow, University College London (UCL), Wohl Virion Center, London, United Kingdom
    • Research theme: Human retroviruses in Sjögren's syndrome and rheumatoid arthritis
    • Lab director: Robin A. Weiss
    • Supervisor: David G. Griffiths
  • Volunteer for the AIDES charity, Le Havre, France
  • Post-doctoral fellow, Lille Biology institute - Lille Pasteur Institute, CNRS-UMR8161, Lille, France France
    • Research theme: Mechanisms of entry of Hepatitis C virus
    • Lab director: Jean Dubuisson
  • Post-doctoral fellow, INSERM UMR 1078, School of medicine of Brest, France
    • Research theme: Prion diseases and EBNA-1-based EBV immune evasion
    • Lab director: Claude Férec
    • Funding: young researcher contract from Inserm
  • Inserm Researcher, Inserm UMR 1078, School of medicine of Brest, France
    • Research themes:
      • Protein misfolding diseases such as prion diseases.
      • EBNA-1-based EBV immune evasion.
      • Dominant-negative mutants of p53
    • Lab director: Claude Férec